Though SUVN-502 failed to meet a phase two study in the US, trial data has shown that the drug shows some promising results on agitational symptoms of Alzheimer’s patients. SUVN-G3031’s clinical trial is expected to be completed in a year and a half.Suven Life Sciences to spend $40 mn on US clinical trials of two molecules targeting Alzheimer#39;s
Though SUVN-502 failed to meet a phase two study in the US, trial data has shown that the drug shows some promising results on agitational symptoms of Alzheimer’s patients. SUVN-G3031’s clinical trial is expected to be completed in a year and a half.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment